-+ 0.00%
-+ 0.00%
-+ 0.00%

ABPRO HOLDINGS ANNOUNCES SUBMISSION OF AN IND APPLICATION TO INITIATE A PHASE 1 CLINICAL TRIAL OF T CELL ENGAGER ABP-102/CT-P72 FOR HER2-POSITIVE CANCERS

Reuters·12/15/2025 12:00:00

Please log in to view news